Retatrutide vs Tirzepatide vs Semaglutide: 2026 Clinical Data Comparison

The landscape of incretinbased obesity pharmacotherapy has transformed rapidly. Semaglutide (15% weight loss), tirzepatide (22.5%), and now retatrutide (28.3%) represent a clear progression in efficacy — each adding a new receptor target. This article presents a direct comparison of all three compounds using 2026 Phase 3 data, covering mechanism, efficacy, safety, and regulatory status.

For research use only. Not for human consumption.